There is not a good reason that I could think of for anyone to buy this.


PURA VIDA!!

Doesn't have far to fall.


PURA VIDA!!

POM-POMS hard at work!! Why?? I don't understand. I'm guessing they are not getting their posting fees.

How is that even possible?

NO $$$$. = NO ADVERTISING = NO SALES

This Company is gasping on fumes!

POM POMS have no shame leading people astray with lies and innuendos.


PURA VIDA!!!

What about Y/E tax sales? There will be no buyers.

PURA VIDA!!

How could Rob Davidson not have understood that this deal was going to sink the ship?

Smart people told him prior to the signing of this toxic deal; that it was poison; and he did it anyway. He is solely to blame for the mess this company finds itself in. Quicksand that you can't get out of!!


Pura Vida!!

No Money!! There would have been a negative cash balance had they not raised some VERY dilutive convertible funding right before the books were closed for the quarter.

Sales WAY DOWN quarter to quarter!! Almost approaching no sales!

DEFAULTED DEBT!! NO WAY TO RAISE MONEY.

CROWN JEWEL patents were sold to a Company that Rob Davidson is President of. (AWFUL CONFLICT OF INTEREST)!

They are clearly boxed into a corner with NO WAY OUT!!

PURA VIDA!!!

We should see their 2nd quarter financials two weeks from today (unless of course they don't file on time again).

Avenir needed to close their last toxic financing on June 28th so they could show positive cash on the balance sheet at quarters end.

You're correct: The numbers will be BAD and UGLY!!! Facts do matter!!

Pura Vida!!

I wonder if Avenir paid the POM-POMS from the proceeds of their latest TOXIC FINANCING?

They work very hard and should get paid!!

POM-POMS are continuously posting old BS to try and pump up these dreadful shares.

Nothing will help!!

With all the Money that Nicole Kidman is making from the astronomical sales of Sera Topicals, I'm just wondering when she actually walks away from this Company and takes her pretty face elsewhere?

Can't wait to see the sales numbers for Q2 when the 10Q comes out in 3 weeks. I'm sure it must be VERY frustrating to Nancy not to have the funding to advertise.

No $$$ = NO ADVERTISING = NO SALES!!!!

DEFAULTED DEBT AND NOW EVEN MORE DEBT THAT HAS DEATH SPIRAL CONVERSION FEATURES!!

It is obvious that this additional debt closed on June 28th so that Avenir would be able to show a small amount of cash on the end of 2nd quarter 10Q. Sad situation!! We'll get to see the 10Q by August 15th.

I'd also bet the funds were needed to pay the auditor to do the 10Q.

The POM-POM GROUP working overtime!! Sign of desperation!

Are the POM-POMS willing to use their own funds to buy "cheap" shares?? \

The answer is and has been a resounding NO!! They are only here to try and mislead YOU to go buy shares. Obviously, it hasn't worked, No one is foolish enough to buy these shares!!

NO $$$$!!!! FLAT SALES!! DEFAULTED DEBT!!! RD is still Chairman after taking the CROWN JEWEL patents to his own private Company.

POM-POMS keep repeating the same old BS while totally ignoring the real fundamentals .

This Company barely has a pulse and POM-POMS keep pumping. VERY SAD!!

PURA VIDA!!

One word for this: UGLY!!!

If repayment is defaulted, then note converts to shares as stated below....


4.2 Conversion Price. The Conversion Price shall equal the Variable Conversion Price (subject to equitable adjustments for stock splits, stock dividends, or rights offerings by the Borrower relating to the Borrower’s securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions, and similar events). “Variable Conversion Price” means seventy percent (70%) multiplied by the Market Price (as defined herein) (representing a discount rate of thirty percent (30%)). “Market Price” means the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. “Trading Price” means, for any security as of any date, the closing bid price on the or applicable exchange or trading market (the “Trading Market”) as reported by a reliable reporting service designated by the Holder (i.e., Bloomberg) or, if the Trading Market is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets.” If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Borrower and the holders of a majority in interest of the Notes being converted for which the calculation of the Trading Price is required in order to determine the Conversion Price of such Notes. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the Trading Market, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

There is absolutely no basis for anything you are saying. NIH is funding the CRADA and the NYSE/Amex would not even consider uplisting if they wouldn't meet required the shareholder equity. Your speculation is totally off base.

Of course it's from 3 years ago. They have NO MONEY to do advertising now.

POM-POMS need to keep posting, so they just regurgitate old stuff.


Pura Vida!!

All the POM-POMS are out in force today.

DESPERATION!!!


PURA VIDA!!

Several points:
1. Mid-Atlantic has always had the right to raise funds away from CUBT. If they do so, it would dilute CUBT's interest in the rabies drug, but not replace it.

2. If you read Mid-Atlantic's press release carefully, you will see that they didn't actually raise ANY MONEY. Their funder has the right to sell shares and then buy shares from Mid-Atlantic at a discount WHEN and AFTER Mid-Atlantic goes public; which they say they hope to do in the next 24 months.

3. IMO; this "press release" is all about NOTHING!!!!

4. Remember that CUBT is "focused" on AMD FIRST!! AND the rabies drug is a secondary, back burner drug when CUBT has the funds to move it forward.

POM-POMS KEEP PUMPING!!!

POM-POMS need to post; even if they have nothing additive.


Pura Vida!!

Let's see what the 2nd qtr sales will be.

NO MONEY = NO ADVERTISING = NO SALES. Sales remain flat. Nancy can't promote product without the money to spend (Her credit Card isn't nearly enough!).

DEFAULTED DEBT = NO NEW WAY TO FINANCE

RD BURIED THIS COMPANY, and he still remains Chairman. You don't need to know more than that.

PURA VIDA!!

Regeneron’s Mkt Cap now over $110B!!!

POM-POMS working Over Time!!!

BUYER BEWARE!!!!

PURA VIDA!!!

While an S1 is active neither Garr or Michaels can transact in CUBT.

Garr and Michaels are FULLY COMMITTED!!!!

It's obvious that the 2 sell orders that were over the market for several days, both became "Market" orders today. My guess, both were from he same seller who needed $$$

Good thing, there is very little now for sale above the market.

What you posted says "Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%.

That means from Q3 2024 to Q4 2024 sales increased by a measly $43,000. Man; isn't the 4th qtr the XMAS quarter where cosmetic sales surge?

NO MONEY = NO SALES!!!


PURA VIDA!!

The "OCULAR" space is very hot as per today's $3B acquisition by Merck/

https://www.merck.com/news/merck-to-acquire-eyebio/

Real facts for real investors come from official company sources which are fully accountable to the SEC for accuracy and truthfulness.

Yes; we finally agree: Real Investors should read the 10K to see the Company has NO MONEY, has DEFAULTED ON ITS DEBT, and is using its CEO's Credit Card to survive!! They also sold their Crown Jewel patents to a Rob Davidson led Company.. Sales are at best stagnant because there's NO MONEY to buy ads.

STUDY THE FACTS!!

BUYER BEWARE!!!

PURA VIDA!!

That action would allow the POM-POMS to continue to mislead investors about this Company.

Don't Go!! You're doing a service.


Pura Vida!!

This Company generates sales by spending MONEY for advertising. No advertising = NO SALES.

Where is the MONEY for advertising going to come from?

The IONIC DEFAULTED DEBT means no investment bank could raise Avenir any capital. Nancy is using her credit card to fund operations, but she has only a limited line of credit.

Rob Davidson got this Company into the IONIC DEBT pit and it can't get out. He is also the CEO of the Company that took the Crown Jewel patents from Avenir as he remains Chairman of Avenir; a real conflict of interest!

PURA VIDA!!

I guess if POM-POMS want to repeat this BS PAID FOR "article; I will repeat my response......

Again; POM-POMS deceiving us with their posts...

This is a "PAID-FOR" article. Read the disclaimer at the bottom which our POM-POMS refer to as media exposure...DISCLAIMER: https://corporateads.com/disclaimer/

Again; POM-POMS deceiving us with their posts...

This is a "PAID-FOR" article. Read the disclaimer at the bottom which our POM-POMS refer to as media exposure...DISCLAIMER: https://corporateads.com/disclaimer/

POM-POMS love posting irrelevant bits of info.

SHOW ME THE MONEY!!!!

IONIC DEFAULTED DEBT!!!

NOBODY WILL FINANCE THIS COMPANY!!!

OTC MARKETS could halt the trading of this Company in 4 more calendar days if their 10K isn't filed!

Pura Vida!

Animal studies are obviously only to prove safety and, as far as I know only humans develop AMD. Clearly if CUBT is moving forward and planning human trials then the animal trials must have shown the safety in animals.

Remember that Metformin has been prescribed as a first line treatment for type 2 diabetes since 1995. CUBT is using Metformin in a topical eye solution.

Remember that NIH through the CRADA will be paying MOST of the IND costs for the AMD trial (all except travel expenses). CUBT has to pay to provide the drug, but NIH will pay for the trial.

CUBT needs to raise enough money to qualify to be uplisted to the NYSE/Amex.